COMPASS Pathways plc Q3 FY2025 earnings call

• Acceleration of launch plans, with potential 9-12 month acceleration announced, including completion of enrollment in the Phase III COMP006 trial.
• Positive interaction with the FDA regarding NDA filing for COMP360 in TRD, including potential for a rolling submission.
• Continued commercial preparations, including strategic collaborations and understanding of the commercial landscape for COMP360.
• Cash position: Cash and cash equivalents were $186 million at the end of the third quarter, with cash runway into 2027 maintained through disciplined spending.

No specific product segment financial performance details provided in the transcript.

• Potential 9-12 month acceleration of launch plans.
• Unblinding of 9-week data from Part A of the COMP006 trial and disclosure concurrently with 26-week data from the COMP005 trial in Q1 next year.
• 26-week data from COMP006 expected in early Q3 next year as the last gating item for NDA submission.
• Confidence in being ready for an accelerated launch, building on commercial learnings and progress in Phase III trials.

No specific risk discussion detailed in the provided transcript beyond general forward-looking statement disclaimers, noting that actual events or results could differ materially from forward-looking statements due to various risks, uncertainties, and factors described in SEC filings.

Q: Congrats on the update and time lines. Quick question about selection of specialty pharma partner you may use to kind of support patient access. Have you identified any that you would anticipate to move forward with? And would there need to be any unique capabilities that they have in terms of offering those patient support services to psychiatrists who would be interested in prescribing psilocybin?

A: Lori Englebert responded that no selection has been made yet, but work is ongoing to understand the distribution pathway, and there are no uniquely unfamiliar requirements for psychiatrists.

Q: So as it relates to this FDA meeting, I think you said previously that the thought was you were only going to be sharing with the agency the same level of granularity on the 005 data that we've seen, and I think you've still -- since just seen as well. To that point, do you feel like there's the need to have another FDA engagement after you release this much more detailed data early next year? And then I guess as a second question related to that, can you help set up what your expectation is when we see 26-week data? And what do you think would be a positive outcome on either the frequency of retreatment or response rates for retreatment that would align with your target product profile as it relates to how -- what you're looking for durability and just kind of the commercial sort of viability and scalability?

A: Kabir Nath and Lori Englebert discussed FDA interaction, noting expected further engagement post-data release in Q1, and discussed expected positive outcomes in 26-week data related to durability and commercial viability.

Q: Congrats on the progress here. Just curious if any of the interactions with the FDA included conversation around submissions for the commissioner's priority review application. I think you had said at some point, you did have interactions with the agency on that submission. And if not, has the agency pointed toward TRD versus PTSD in any way being higher areas of unmet need in their view?

A: Kabir Nath and Steve Levine discussed FDA interactions, noting positive feedback from the division, and both TRD and PTSD are seen as areas of unmet need, with COMPASS advanced in TRD.

Q: By presenting the 006 data at 9 weeks, do you risk the integrity of the study in any way? Like I know that was part of FDA discussions previously. So I'm curious what led regulators to change their stance? And also curious if by presenting this data at an earlier time point, do you lose the commercial ability to make claims around the durability of the 2-dose regimen?

A: Kabir Nath and Lori Englebert addressed study integrity, stating no compromise to the study and that data presentation does not risk commercial claims on durability.

Q: Could you please review the state of your commercialization preparation for 360 and provide more color on what activities you pulled forward given the accelerated time lines? And then I have another follow-up.

A: Lori Englebert talked about commercial preparation activities pulled forward, including marketing, messaging, sales force structuring, and market access/payer discussions, building on prior strategic collaborations and learnings.

Q: The first question is just on the Type B meeting with the FDA. I'm wondering if there was any change from what had been discussed previously. Or just has the agency's tone or the way that they're talking to you about COMP360, has this changed from what you've heard previously, And particularly as it relates to the potential for the rolling submission and how we should think about that? And then I have a few follow-ups.

A: Kabir Nath and Steve Levine discussed FDA meeting tone, positive spirit around rolling submissions, and commercial readiness of SPRAVATO sites.

Q: As a point of clarification, what is the key variable that has allowed you to bring forward your time line for commercialization by 9 to 12 months? Is that related primarily to an ability to submit an NDA for COMP360 for treatment-resistant depression ahead of your original plans? Or is it something else? And second, is it fair to assume that you would need to have the Part A from COMP006 and Part B from COMP005 in hand to initiate a rolling NDA submission?

A: Kabir Nath discussed key variables including completion of COMP006 enrollment and potential for rolling submission with preclinical and CMC submissions ahead of full clinical data.